FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

CRAVES FRED B 		2. Issuer Name and Ticker or Trading Symbol

SYNTA PHARMACEUTICALS CORP [ MDGL ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/22/2016
(Street)

SAN FRANCISCO, CA 94111
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   7/22/2016     A    296067   (1) A $0   296067   D    
Common Stock   7/22/2016     A    5538474   (1) A $0   5538474   I   Bay City Capital Fund IV, L.P. ("Fund IV")   (2)
Common Stock   7/22/2016     A    119380   (1) A $0   119380   I   Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment")   (3)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Shares issued relate to the exchange of shares of Madrigal Pharmaceuticals, Inc. (as a private company) for shares of Synta Pharmaceuticals Corp. per Synta's agreement to acquire Madrigal, dated April 13, 2016. After the completion of the Merger, Synta Pharmaceuticals Corp. changed its name to Madrigal Pharmaceuticals, Inc.
( 2)  Dr. Craves disclaims beneficial ownership of these securities owned by Fund IV, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Fund IV's general partner, Bay City Capital Management IV LLC.
( 3)  Dr. Craves disclaims beneficial ownership of these securities owned by Co-Investment, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Bay City Capital LLC, which is the manager of Co-Investment's general partner, Bay City Capital Management IV LLC.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
CRAVES FRED B
C/O BAY CITY CAPITAL, LLC
750 BATTERY STREET, SUITE 400
SAN FRANCISCO, CA 94111 		X X


Signatures
/s/ Fred B. Craves 7/26/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
過去 株価チャート
から 10 2024 まで 11 2024 Synta Pharmaceuticals Corp. (MM)のチャートをもっと見るにはこちらをクリック
Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
過去 株価チャート
から 11 2023 まで 11 2024 Synta Pharmaceuticals Corp. (MM)のチャートをもっと見るにはこちらをクリック